Inhibikase Therapeutics (IKT) Asset Utilization Ratio (2021 - 2024)
Inhibikase Therapeutics (IKT) has disclosed Asset Utilization Ratio for 4 consecutive years, with 0.0 as the latest value for Q3 2024.
- Quarterly Asset Utilization Ratio fell 100.0% to 0.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was 0.0 through Sep 2024, down 100.0% year-over-year, with the annual reading at 0.01 for FY2023, 260.65% up from the prior year.
- Asset Utilization Ratio for Q3 2024 was 0.0 at Inhibikase Therapeutics, down from 0.01 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.14 in Q1 2021, with the low at 0.0 in Q3 2024.
- Average Asset Utilization Ratio over 4 years is 0.03, with a median of 0.02 recorded in 2024.
- The sharpest move saw Asset Utilization Ratio skyrocketed 715.42% in 2023, then crashed 100.0% in 2024.
- Over 4 years, Asset Utilization Ratio stood at 0.07 in 2021, then crashed by 93.43% to 0.0 in 2022, then skyrocketed by 248.72% to 0.02 in 2023, then plummeted by 100.0% to 0.0 in 2024.
- According to Business Quant data, Asset Utilization Ratio over the past three periods came in at 0.0, 0.01, and 0.02 for Q3 2024, Q2 2024, and Q1 2024 respectively.